Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Laudani

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Heart (British Cardiac Society)|June 26, 2026
Optimal timing of aspirin discontinuation after acute coronary syndrome treated with percutaneous coronary intervention: a systematic review and meta-analysisKamil Bujak, Claudio Laudani, Riccardo Rinaldi, et al.
Expert Opinion on Drug Safety|November 10, 2025
Safety and optimal use of direct oral anticoagulant therapyClaudio Laudani, Luis Ortega-Paz, Ali Zgheib, et al.
Thrombosis and Haemostasis|August 4, 2025
Factor XI Inhibitors or Direct Oral Anticoagulants in Atrial Fibrillation: A Focused Meta-analysisClaudio Laudani, Davide Capodanno, Felice Gragnano, et al.
International Journal of Cardiology|September 15, 2025
Predictors of discontinuation and non-publication of heart failure clinical trials: A cross-sectional analysis of ClinicalTrials.gov dataMohmmad M Alawajneh, Ahmed Aljabali, Laith Theeb, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|December 22, 2025
Long-term outcomes of percutaneous coronary intervention for recurrent events in patients undergoing target-vessel vs. nontarget-vessel revascularizationSimone Finocchiaro, Maria Sara Mauro, Claudio Laudani, et al.
Thrombosis and Haemostasis|October 10, 2025
Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Platelet Reactivity in Patients with Atherosclerotic Cardiovascular Disease: A Pooled Analysis of Two Randomized Double-blind Placebo-controlled StudiesLuis Ortega-Paz, Yasushi Ueki, Claudio Laudani, et al.
JACC. Cardiovascular Interventions|August 13, 2025
Aspirin or P2Y<sub>12</sub> Inhibitor Monotherapy After Percutaneous Coronary Intervention for Acute Coronary SyndromesClaudio Laudani, Daniele Giacoppo, Giovanni Occhipinti, et al.
Journal of Cardiovascular Development and Disease|May 26, 2026
In Hospital Assessment and Management of High Bleeding Risk in Patients with ST-Elevation Myocardial Infarction (STEMI)Sanghoon Kim, Alberto Piserra-López, Salvatore Giordano, et al.
JACC. Advances|August 12, 2024
Assessment of Noninferiority Margins in Cardiovascular Medicine TrialsAntonio Greco, Marco Spagnolo, Claudio Laudani, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 25, 2024
P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysisMattia Galli, Claudio Laudani, Giovanni Occhipinti, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Heart (British Cardiac Society)|June 26, 2026
Optimal timing of aspirin discontinuation after acute coronary syndrome treated with percutaneous coronary intervention: a systematic review and meta-analysisKamil Bujak, Claudio Laudani, Riccardo Rinaldi, et al.
Expert Opinion on Drug Safety|November 10, 2025
Safety and optimal use of direct oral anticoagulant therapyClaudio Laudani, Luis Ortega-Paz, Ali Zgheib, et al.
Thrombosis and Haemostasis|August 4, 2025
Factor XI Inhibitors or Direct Oral Anticoagulants in Atrial Fibrillation: A Focused Meta-analysisClaudio Laudani, Davide Capodanno, Felice Gragnano, et al.
International Journal of Cardiology|September 15, 2025
Predictors of discontinuation and non-publication of heart failure clinical trials: A cross-sectional analysis of ClinicalTrials.gov dataMohmmad M Alawajneh, Ahmed Aljabali, Laith Theeb, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|December 22, 2025
Long-term outcomes of percutaneous coronary intervention for recurrent events in patients undergoing target-vessel vs. nontarget-vessel revascularizationSimone Finocchiaro, Maria Sara Mauro, Claudio Laudani, et al.
Thrombosis and Haemostasis|October 10, 2025
Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Platelet Reactivity in Patients with Atherosclerotic Cardiovascular Disease: A Pooled Analysis of Two Randomized Double-blind Placebo-controlled StudiesLuis Ortega-Paz, Yasushi Ueki, Claudio Laudani, et al.
JACC. Cardiovascular Interventions|August 13, 2025
Aspirin or P2Y<sub>12</sub> Inhibitor Monotherapy After Percutaneous Coronary Intervention for Acute Coronary SyndromesClaudio Laudani, Daniele Giacoppo, Giovanni Occhipinti, et al.
Journal of Cardiovascular Development and Disease|May 26, 2026
In Hospital Assessment and Management of High Bleeding Risk in Patients with ST-Elevation Myocardial Infarction (STEMI)Sanghoon Kim, Alberto Piserra-López, Salvatore Giordano, et al.
JACC. Advances|August 12, 2024
Assessment of Noninferiority Margins in Cardiovascular Medicine TrialsAntonio Greco, Marco Spagnolo, Claudio Laudani, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 25, 2024
P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysisMattia Galli, Claudio Laudani, Giovanni Occhipinti, et al.
Pageof 8